Editor’s note: Dr. William Miller, chief of staff at the Adventist Health Mendocino Coast Hospital, is writing weekly reports concerning the COVID-19 situation on the Mendocino Coast. We are pleased to be running his health column, with details on the medical fight against the pandemic. The views shared in this weekly column are those of the author, Dr. William Miller, and do not necessarily represent those of The Mendocino Voice or of Adventist Health.
A new antiviral treatment that helps suppress replication of the SARS-2 virus is likely to receive Emergency Use Authorization (EUA) by the FDA in the next three weeks. SARS-2 is the coronavirus that causes COVID. This new treatment is a pill made by Merck Pharmaceuticals named molnupiravir, reportedly getting its name from the Scandinavian word Mjölnir meaning Thor’s Hammer. While the name strikes me as a bit presumptuous, the medication does hold promise. Molnupiravir will be marketed under the brand name Lagevrio.
Continue reading for FREE
We just want to make sure you’re a human! Sign in to keep reading and receive our weekday newsletter in your inbox.
Success! Your account was created and you’re signed in.
Please visit My Account to manage your account.